StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) company profile

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302545% above fair value
$411.29−5.25 (-1.26%)

Close on Nov 16, 2026Market cap $46.76BP/E 73.6Yield –

About BeOne Medicines

Pharmaceutical Preparations, SIC 2834

BeOne is a global biopharmaceutical organization focused on discovering, developing, and commercializing treatments for cancer patients worldwide. The enterprise concentrates its clinical pipelines and commercial activities primarily on hematology and solid tumor oncology. Its commercialized portfolio includes internally developed therapies such as the Bruton's tyrosine kinase inhibitor BRUKINSA, the anti-PD-1 monoclonal antibody TEVIMBRA, the B-cell lymphoma 2 inhibitor sonrotoclax, and the PARP inhibitor PARTRUVIX, alongside various in-licensed therapies covering diverse hematologic and solid malignancies. Its customer base consists of healthcare systems, hospitals, and cancer patients accessing therapies through public and private healthcare reimbursement frameworks.

The company operates on an international scale, marketing and commercializing products across more than 60 countries and regions, including extensive availability of core treatments in over 75 markets globally. BeOne maintains clinical operations across six continents supported by internal development and manufacturing infrastructure, with primary operational subsidiaries situated in the United States, China, the United Kingdom, and Australia. The enterprise is incorporated and headquartered in Switzerland.

Summary of the business section of BeOne Medicines's latest annual report, written by StockData.

Company profile

Company

Legal name
BeOne Medicines Ltd.
Founded
2010
Headquarters
Basel, Switzerland
Address
C/O Beone Medicines I Gmbh, Aeschengraben 27, 21st Floor 4051
Phone
41-616851900
Employees
12,000, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Ernst& Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ONC
Other tickers
BEIGF
Former tickers
BGNE until Jan 8, 2025
Exchange
Nasdaq
IPO date
Feb 3, 2016
Shares outstanding
1.48B, Jul 31, 2026
Public float
$14.70B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1651308
CUSIP
07725L102
ISIN
US07725L1026
FIGI
BBG00B6WF7T5
Share class FIGI
BBG00B6WF7V2
LEI
549300JFUK6FRD5MH739
EIN
98-1209416

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John OylerChief Executive Officer, Director7,815,448
Titus B. BallPrincipal Accounting Officer0
Chan Henry LeeSVP, General Counsel0
Xiaobin WuPresident and COO4,000
Aaron RosenbergChief Financial Officer0
Lai WangPresident, Global Head of R&D601,965
Xiaodong WangDirector4,586,980
Bros. Advisors Lp BakerDirector922,957
Brothers Life Sciences LP BakerDirector8,229,958
Felix BakerDirector997,946
Bros. Advisors (GP) LLC BakerDirector730,643
667, L.P.Director10,803,789
Julian BakerDirector10,734,144
Elizabeth Fisher MooneyDirector18,980
Margaret DuganDirector73,164
Anthony C. HooperDirector83,720
Shalini SharpDirector38,116
Olivier BrandicourtDirector46,306
Alessandro RivaDirector73,164
Charles Lazelle SawyersDirector1,946
Qingqing YiDirector0
Corazon (Corsee) D. SandersDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$17.94M$60.67M$10.46M$118$125
FY2024$20.84M$14.97M$7.94M$71$93
FY2023$18.93M$11.43M$7.11M$70$94
FY2022$18.05M$11.22M$6.36M$85$90
FY2021$16.75M$22.88M$5.14M$105$100
FY2020$14.41M$40.75M$5.18M$156$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
$1.13M$11.25M$3.75M$1.68M$133.83K$17.94M-14%
Aaron Rosenberg
Chief Financial Officer
$660.00K$3.87M$1.29M$586.08K$21.00K$6.43M+5%
Dr. Xiaobin Wu
President and Chief Operating Officer
$862.41K$7.50M$2.50M$957.28K$210.00K$12.03M+8%
Dr. Lai Wang
President, Global Head of Research and Development
$659.49K$15.25M$1.75M$585.63K$74.70K$18.32M+147%
Chan Lee
Senior Vice President, General Counsel and Corporate Secretary
$654.00K$2.85M$949.88K$580.75K$21.00K$5.06M+8%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 3, 2016
Offer price
$24.00
Securities offered
6,600,000
Gross proceeds
$158.40M
Exchange
Nasdaq
First trading day
Feb 3, 2016
First-day close
$28.32+18.0%
Lock-up ends (est.)
Aug 1, 2016

“The initial public offering price is $24.00 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

Corporate history

Events identified from SEC filings

See a number that looks wrong?